With the patent for Clobex (clobetasol propionate) facing an expiration of September 22, 2017, this prescription medication used to treat adults and children 12 years and older with psoriasis is sure to have generic development. Clobetasol propionate is available as a topical steroid spray, and it is effectual as it decreases inflammation and suppresses an overactive immune system, which is thought to contribute to psoriasis.
Clobetasol propionate successfully relieves one of the most troubling symptoms of psoriasis, which is itching. Roughly 7.5 million Americans are estimated to have psoriasis, and the vast majority of these patients report that while they are stressed due to the outward appearance of psoriasis, itchiness is the symptom they have the hardest time dealing with.
However, itchiness and embarrassment are not the only symptoms of this burdensome condition, depression is also a symptom spawned from psoriasis as well. A study conducted by the University of Pennsylvania, indicated that psoriasis patients had a 39 percent increase in the risk of the clinical diagnosis of depression. In addition, psoriasis patients had a 44 percent increase in the risk of suicidal tendencies. Topical treatments like Clobetasol should be considered by practitioners alongside medical or therapeutic treatment for depression, if needed, for patients with psoriasis on a regular basis.
Clobex Spray (clobetasol propionate) was used in the initial phase of a new study evaluating the treatment of moderate to severe plaque psoriasis in adults. This study, conducted by Galderma Laboratories, indicates that the sequential treatment of plaque psoriasis with Clobex Spray followed by Vectical Ointment is effective in managing plaque psoriasis over a 12-week period. Results were presented at the 67th Annual Meeting of the American Academy of Dermatology, and they revealed success for patients who used Clobex Spray 0.05% followed by treatment with Vectical (calcitriol) Ointment 3mcg/g. This study was also conducted to confirm the safety and efficacy of these products when used in a sequential regimen. This regimen was well tolerated for the vast majority of patients, with the most commonly reported side effects being mild to moderate pruritus and stinging.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.